Trial · NCT07894900
Twenty-five Years of Advanced RadioTherapy at San Raffaele Hospital
NCT07894900, Not yet recruiting, IRCCS San Raffaele
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Twenty-five Years of Advanced RadioTherapy at San Raffaele Hospital. Trials, record NCT07894900. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894900
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Twenty-five Years of Advanced RadioTherapy at San Raffaele Hospital
- NCT number
- NCT07894900
- Status
- Not yet recruiting
- Enrollment
- 10,000 participants, estimated
- Lead sponsor
- IRCCS San Raffaele
- Conditions
- Malignant Tumor, Benign Neoplasm, Parkinson Disease, Trigeminal Neuralgia, Arteriovenous Malformations
- Interventions
- Advanced radiotherapy techniques
- First posted
- 2026-10-26
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Local Relapse Free Survival | From the date of radiotherapy end until the date of local progression or date of death from any cause, whichever came first, assessed up to 5 years | Local control of the disease (at the treated site) |
| Primary | Biochemical Relapse Free Survival | From the date of radiotherapy end until the date of biochemical progression or date of death from any cause, whichever came first, assessed up to 5 years | Biochemical control for prostate cancer |
| Primary | Obliteration rate | Up to 5 years after the treatment | Obliteration rate of arteriovenous malformations |
| Primary | Improvement of clinical symptoms | Up to 5 years after the treatment | BNI (Barrow National Institute) scale for trigeminal neuralgia, a 5-point grading system, from Grade I (Excellent outcome) without pain to Grade V (Poor treatment response) with trigeminal pain with no improvement despite treatment |
| Primary | Functional improvement after the treatment | Up to 5 years after the treatment | TETRAS score or UPDRS for movement disorders, which includes two scales, Activities of Daily Living Scale with 12 items and a range of points from 0 to 48 and Performance scale with 9 items and a range of points from 0 to 64. Lower means less tremor on both subscales, and the two are reported separately rather than summed |
| Secondary | Marginal Relapse Free Survival | Up to 5 years after the treatment | Marginal relapses for brain tumors |
| Secondary | Regional Relapse Free Survival | Up to 5 years after the treatment | Relapses in regional lymph-nodes |
| Secondary | Distant Metastasis Free Survival | Up to 5 years after the treatment | Distant recurrences |
| Secondary | Clinical Relapse Free Survival | Up to 5 years | Absence of local, regional and distant relapses during the follow-up |
| Secondary | Cancer Specific Survival | From the date of radiotherapy end until the date of death from disease progression, assessed up to 5 years | Cancer Survival |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers17
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894900
GET https://conductscience.org/api/trials/v1/NCT07894900/registered